EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Coumarin‐Based Allosteric Inhibition of PTP1B : A Potential Strategy for Metabolic Regulation

Emadeldin M Kamel iD, Doaa A Abdelrheem, Faris F Aba Alkhayl, Fahad M Alshabrmi, May Bin-Jumah, Abdullah S Alawam, Al Mokhtar Lamsabhi

Journal of Molecular Recognition · 2025

DOI: 10.1002/jmr.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Recognition, 2025. Verfasst von Emadeldin M Kamel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 1, Coumarins, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia, Innovacion y Universidades in Spain, Princess Nourah Bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein Tyrosine Phosphatase 1B (PTP1B) is a key metabolic regulator and a promising therapeutic target for type 2 diabetes and obesity. This study evaluated the inhibitory potential of four coumarins—Bergapten, Imperatorin, Xanthotoxol, and Isopimpinellin, isolated from Ammi majus —through in silico and in vitro approaches. Molecular docking and molecular dynamics (MD) simulations identified Bergapten and Imperatorin as the most stable binders, forming key π–π stacking interactions with Phe280 and Phe196. Principal Energy Landscape (PEL) analysis further confirmed their stable binding conformations, while MM/PBSA calculations ranked Bergapten (−17.21 ± 0.80 kcal/mol) and Imperatorin (−12.76 ± 2.99 kcal/mol) as the strongest binders. ADMET analysis indicated high gastrointestinal absorption, blood–brain barrier permeability, and favorable drug‐like properties for all compounds. In vitro PTP1B inhibition assays validated these findings, with Bergapten (IC 50 = 6.64 ± 0.23 μM) and Imperatorin (IC 50 = 9.44 ± 1.05 μM) exhibiting potent inhibition, comparable to the reference inhibitor ursolic acid (IC 50 = 7.43 ± 0.74 μM), whereas Xanthotoxol (IC 50 = 28.60 ± 1.88 μM) and Isopimpinellin (IC 50 = 25.48 ± 1.98 μM) showed significantly weaker inhibition. Enzyme kinetics revealed noncompetitive inhibition mechanisms, with K i values of 6.73 μM and 8.44 μM for Bergapten and Imperatorin, respectively, suggesting allosteric binding. These results highlight Bergapten and Imperatorin as promising allosteric inhibitors of PTP1B, warranting further cell‐based and preclinical investigations for potential therapeutic applications in metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 1CoumarinsEnzyme InhibitorsMolecular Dynamics SimulationHumansMolecular Docking SimulationAllosteric RegulationFurocoumarinsProtein Binding

Stichwörter der Autor:innen

allosteric inhibitionenzyme kineticsin vitrometabolic disordersprotein tyrosine phosphatase

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 1CoumarinsPTPN1 protein, humanEnzyme InhibitorsFurocoumarinsimperatorincoumarin

Autor:innen und Institutionen

  • Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
  • Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
  • Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
  • Departamento de Química, Módulo 13, Universidad Autónoma de Madrid, Campus de Excelencia UAM-CSIC Cantoblanco, Madrid, Spain.
  • Institute for Advanced Research in Chemical Sciences (IAdChem), Universidad Autónoma de Madrid, Madrid, Spain.

ORCID-Profile: Emadeldin M Kamel

Förderung

  • Ministerio de Ciencia, Innovacion y Universidades in Spain
  • Princess Nourah Bint Abdulrahman University

Zitieren

APA

Kamel, E. M., Abdelrheem, D. A., Aba Alkhayl, F. F., Alshabrmi, F. M., Bin-Jumah, M., Alawam, A. S., & Lamsabhi, A. M. (2025). Coumarin‐Based Allosteric Inhibition of PTP1B : A Potential Strategy for Metabolic Regulation. Journal of Molecular Recognition. https://doi.org/10.1002/jmr.70006

Vancouver

Kamel EM, Abdelrheem DA, Aba Alkhayl FF, Alshabrmi FM, Bin-Jumah M, Alawam AS, et al. Coumarin‐Based Allosteric Inhibition of PTP1B : A Potential Strategy for Metabolic Regulation. Journal of Molecular Recognition. 2025. doi:10.1002/jmr.70006

BibTeX
@article{Kamel2025,
  author = {Kamel, Emadeldin M and Abdelrheem, Doaa A and Aba Alkhayl, Faris F and Alshabrmi, Fahad M and Bin-Jumah, May and Alawam, Abdullah S and Lamsabhi, Al Mokhtar},
  title = {Coumarin‐Based Allosteric Inhibition of PTP1B : A Potential Strategy for Metabolic Regulation},
  journal = {Journal of Molecular Recognition},
  year = {2025},
  doi = {10.1002/jmr.70006}
}
Kostenlos starten →